Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.
Company Details
- Employees
- 29
- Founded
- -
- Address
- Boston, Massachusetts 02139, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Boston, Massachusetts
Delix Therapeutics Questions
Delix Therapeutics's website is https://www.delixtherapeutics.com
Delix Therapeutics's LinkedIn profile is https://www.linkedin.com/company/delix-therapeutics
Delix Therapeutics has
29 employees.
View email and phone details for 29
employees at Delix Therapeutics.
Delix Therapeutics's industry is
Biotechnology Research
Delix Therapeutics's top competitors are
Mindmed,
Gilgamesh Pharmaceuticals,
Beckley Psytech,
Sensorium Therapeutics,
Atai Life Sciences,
Aurion Biotech,
Lykos Therapeutics,
Seaport Therapeutics,
Compass Pathways,
Cybin Inc.
Delix Therapeutics's categories are Biotechnology Research
Delix Therapeutics's founding year is 2019
